Molecular characterization of liver gene transfer and its oncogenic potential A substantial advantage of AAV for genetic diseases is its ability to confer long-term and high-level transgene expression in liver. This project will evaluate several interesting aspects of molecular biology as it relates to mechanisms of persistence and potential safety considerations. The first specific aim will address the potential for recombination between the transduced vector genome and the latent wild-type AAV that occurs subsequent to a natural infection. The second specific aim will undertake a systematic evaluation of the molecular state and structure of persistent AAV genomes with a focus on the frequency and distribution of integration sites by adapting the state-of-art massive parallel genome wide pyrosequencing technology for studying AAV integration. The final specific aim will undertake experiments to actually quantitate the oncogenic potential of AAV following the delivery to liver. These studies will be performed in two murine models for dyslipidemia including LDLR/Apobec-1 double KO and LDLR/Apobec-1/MTP triple KO mice. In addition, the consequence of chronic inflammation caused by steatohepatitis on the oncogenic potential of AAV will be studied Project III will rely on Projects I and II for obtaining tissues from nonhuman primates who have received AAV vectors as part of its goal to undertake molecular characterization. This project will rely on the expertise of Dr. Rader in Project II to conduct the tumors studies in the murine models for lipidemia.

Public Health Relevance

Lay description. This project will evaluate the molecular structure of the transferred gene as is resides in the liver cells. Animal studies will be performed to determine if the vector causes tumors.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL059407-14
Application #
8378199
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
14
Fiscal Year
2012
Total Cost
$463,117
Indirect Cost
$17,888
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ibrahim, Salam; Somanathan, Suryanarayan; Billheimer, Jeffrey et al. (2016) Stable liver-specific expression of human IDOL in humanized mice raises plasma cholesterol. Cardiovasc Res 110:23-9
Ajufo, Ezim; Cuchel, Marina (2016) Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia. Curr Atheroscler Rep 18:22
Rashnonejad, Afrooz; Chermahini, Gholamhossein Amini; Li, Shaoyong et al. (2016) Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene. Mol Biotechnol 58:30-6
Halder, Sujata; Van Vliet, Kim; Smith, J Kennon et al. (2015) Structure of neurotropic adeno-associated virus AAVrh.8. J Struct Biol 192:21-36
Xie, Jun; Burt, Daniel Robert; Gao, Guangping (2015) Adeno-associated virus-mediated microRNA delivery and therapeutics. Semin Liver Dis 35:81-8
Bissig-Choisat, Beatrice; Wang, Lili; Legras, Xavier et al. (2015) Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. Nat Commun 6:7339
Wang, Lili; Bell, Peter; Somanathan, Suryanarayan et al. (2015) Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol Ther 23:1877-87
Wang, Qiang; Lock, Martin; Prongay, Andrew J et al. (2015) Identification of an adeno-associated virus binding epitope for AVB sepharose affinity resin. Mol Ther Methods Clin Dev 2:15040
Ahmed, Seemin S; Gao, Guangping (2015) Making the White Matter Matters: Progress in Understanding Canavan's Disease and Therapeutic Interventions Through Eight Decades. JIMD Rep 19:11-22
Wang, Dan; Gao, Guangping (2014) State-of-the-art human gene therapy: part I. Gene delivery technologies. Discov Med 18:67-77

Showing the most recent 10 out of 140 publications